Research Output per year
Personal profile
Research Interests
Cancer immunotherapy has represented a paradigm shift in cancer therapy. However, at present immunotherapies help only a minority of patients and in certain types of cancer they are unsuccessful due to the overriding immunosuppression mechanisms in the tumour microenvironment (TME). The mechanisms underlying the immunoinhibitory activities of the TME are presently poorly understood. My research aims to apply various molecular biological techniques to discover novel non-enzymatic modulators of key pro-inflammatory signalling pathways. This could potentially identify and target key protein-protein interactions in order to release the “natural brakes” of inflammatory signalling pathways in innate immune cells. This research will advance our understanding of the regulatory mechanisms of innate immune cell signalling in the host’s response to pathogens and cancer leading to the development of a new class of innate immunotherapies, which will be able to convert immunological “cold” tumours (e.g. prostate, glioblastoma, ovarian and pancreatic cancer) into ones that are responsive to immunotherapy.
Education/Academic qualification
Post-doctoral Research Fellow, Imperial College London
1 Jan 2011 → 31 Dec 2018
PhD, Doctorate, University College Dublin
31 Oct 2004 → 1 Nov 2009
External positions
Honorary Research Fellow, Imperial College London
1 Jan 2019 → …Keywords
- RM Therapeutics. Pharmacology
- Cancer Immunotherapy
- Innate Immune Signalling
- Tumor Microenvironment
- Metabolism
Fingerprint Dive into the research topics where Jason Bennett is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 2 Similar Profiles
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Research Output
Clinical proof of concept for a safe and effective NF-κB-targeting strategy in multiple myeloma
Tornatore, L., Capece, D., D'Andrea, D., Begalli, F., Verzella, D., Bennett, J., Acton, G., Campbell, E. A., Kelly, J., Tarbit, M., Adams, N., Bannoo, S., Leonardi, A., Sandomenico, A., Raimondo, D., Ruvo, M., Chambery, A., Oblak, M., Al-Obaidi, M. J., Kaczmarski, R. S. & 1 others, , May 2019, In : British Journal of Haematology. 185, 3, p. 588-592 5 p.Research output: Contribution to journal › Letter
5
Citations
(Scopus)
Cocaine addicted to cytoskeletal change and a fibrosis high
Verma, A., Bennett, J., Örme, A. M., Polycarpou, E. & Rooney, B., 1 Feb 2019, In : Cytoskeleton. 76, 2, p. 177-185 9 p.Research output: Contribution to journal › Review article
1
Citation
(Scopus)
Preclinical toxicology and safety pharmacology of the first-in-class GADD45β/MKK7 inhibitor and clinical candidate, DTP3
Tornatore, L., Capece, D., D'Andrea, D., Begalli, F., Verzella, D., Bennett, J., Acton, G., Campbell, E. A., Kelly, J., Tarbit, M., Adams, N., Bannoo, S., Leonardi, A., Sandomenico, A., Raimondo, D., Ruvo, M., Chambery, A., Oblak, M., Al-Obaidi, M. J., Kaczmarski, R. S. & 8 others, , 2019, In : Toxicology Reports. 6, p. 369-379 11 p.Research output: Contribution to journal › Article
Open Access
File
3
Citations
(Scopus)
6
Downloads
(Pure)
GADD45β Loss Ablates Innate Immunosuppression in Cancer
Verzella, D., Bennett, J., Fischietti, M., Thotakura, A. K., Recordati, C., Pasqualini, F., Capece, D., Vecchiotti, D., D'Andrea, D., Di Francesco, B., De Maglie, M., Begalli, F., Tornatore, L., Papa, S., Lawrence, T., Forbes, S. J., Sica, A., Alesse, E., Zazzeroni, F. & Franzoso, G., Mar 2018, In : Cancer Research. 78, 5, p. 1275-1292 18 p.Research output: Contribution to journal › Article
10
Citations
(Scopus)
NF-κB in the crosshairs: Rethinking an old riddle
Bennett, J., Capece, D., Begalli, F., Verzella, D., D'Andrea, D., Tornatore, L. & Franzoso, G., Feb 2018, In : International Journal of Biochemistry and Cell Biology. 95, p. 108-112 5 p.Research output: Contribution to journal › Article
Open Access
File
10
Citations
(Scopus)
9
Downloads
(Pure)